Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKT2152 + palbociclib
- Development stage
- Unknown
- Lead developer
- NiKang Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NKT2152 + palbociclib is a combination therapy under investigation for advanced or metastatic clear cell renal cell carcinoma (ccRCC). **NKT2152** is a highly selective, orally bioavailable small molecule inhibitor of hypoxia-inducible factor 2 alpha (HIF2α), which plays a critical role in ccRCC tumorigenesis. **Palbociclib** is a small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor that induces cell cycle arrest by blocking the phosphorylation of the retinoblastoma protein, thereby inhibiting tumor cell proliferation. This combination is being studied for its potential synergistic effect in targeting both tumor cell cycle progression and hypoxia-driven pathways in ccRCC[2][5][7].
- Brand names
- Ibrance
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)EPAS1 (Hypoxia-inducible factor 2-alpha)
Beyond the preview
Go deeper on NKT2152 + palbociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKT2152 + palbociclib.